Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 14,607 | 17,971 | 17,054 | 18,003 | 18,932 |
| Gross Profit | 14,607 | 17,971 | 17,054 | 18,003 | 18,932 |
| Operating Expenses | 44,461 | 42,156 | 49,820 | 52,889 | 49,962 |
| Operating Income | -29,854 | -24,185 | -32,766 | -34,886 | -31,030 |
| Interest Expense | 2,581 | 2,355 | 2,563 | 3,441 | 3,151 |
| Other Income | 3,249 | 3,487 | 3,809 | 4,298 | 4,664 |
| Pre-tax Income | -29,186 | -23,053 | -31,520 | -34,029 | -29,517 |
| Income Tax | -363 | -395 | -363 | -622 | -1,410 |
| Net Income Continuous | -28,823 | -22,658 | -31,157 | -33,407 | -28,107 |
| Net Income | $-28,823 | $-22,658 | $-31,157 | $-33,407 | $-28,107 |
| EPS Basic Total Ops | -1.36 | -1.07 | -1.47 | -1.58 | -1.34 |
| EPS Basic Continuous Ops | -1.36 | -1.07 | -1.47 | -1.58 | -1.34 |
| EPS Diluted Total Ops | -1.36 | -1.07 | -1.47 | -1.58 | -1.34 |
| EPS Diluted Continuous Ops | -1.36 | -1.07 | -1.47 | -1.58 | -1.34 |
| EPS Diluted Before Non-Recurring Items | -1.36 | -1.07 | -1.47 | N/A | N/A |
| EBITDA(a) | $-30,577 | $-23,826 | $-32,120 | $-33,970 | $-30,425 |